tickrz reports
tickrz rank
D
Edwards Lifesciences Corp (EW)
Healthcare | Health Services
110.34  -1.24%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 404Warren Buffett RankB / 225
Pure Value RankD / 444Dividend RankD / NO DIVIDEND
Moat RankA / 62Financial Strength RankA / 8
Growth RankA / 31Momentum RankC / 369
EW vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
EWSECTORS&P 500
P/E RATIO34.1832.119.28
EV/EBITDA RATIO24.561711.77
P/S RATIO7.573.62.03
P/B RATIO8.335.53.09
QUALITY
RETURN ON EQUITY26.47%15.64%13.82%
RETURN ON CAPITAL37.36%50.61%10.04%
NET MARGIN19.22%8.18%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY35%
INTEREST COVERAGE45.31x
CURRENT RATIO4.06
GROWTH
5 YR EPS GROWTH21.4%
5 YR SPS GROWTH12.04%
5 YR BPS GROWTH16.12%
About tickrz
Key Concepts
Great Investors
Edwards Lifesciences Corp 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank D / 404
Edwards Lifesciences Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 444Warren Buffett ranking B / 225
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 34.2x, a P/B ratio of 8.3x, a P/S ratio of 7.6x, and an EV/EBITDA ratio of 24.6x. Edwards Lifesciences Corp ranks 444 out of the S&P 500 constituents on valuation--a relatively weak score.Edwards Lifesciences Corp ranks 225 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Edwards Lifesciences Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

quality
moat A / 62financial strength A / 8
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector. Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 45.31x, a debt/equity ratio of 35% and a Moat Rank of 62 translate to a strong Financial Strength score.


momentum C / 369
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.83% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 369. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 31
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.

Edwards Lifesciences Corp (EW)
Healthcare | Health Services
110.34  -1.24%


tickrz rank
D
VALUATION RATIOS
P/E Ratio34.18x
P/B Ratio8.33x
P/S Ratio7.57x
EV/EBITDA Ratio24.56x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY35%
INTEREST COVERAGE45.31x
CURRENT RATIO4.06
MOAT
ROE26.47%
ROIC37.36%
Net Margin19.22%
GROWTH
5 YR EPS GROWTH21.4%
5 YR SPS GROWTH12.04%
5 YR BPS GROWTH16.12%

TICKRZ RANK
Edwards Lifesciences Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 34.2x, a P/B ratio of 8.3x, a P/S ratio of 7.6x, and an EV/EBITDA ratio of 24.6x. Edwards Lifesciences Corp ranks 444 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Edwards Lifesciences Corp ranks 225 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Edwards Lifesciences Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 45.31x, a debt/equity ratio of 35% and a Moat Rank of 62 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.83% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 369. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

VALUE + YIELD
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.